Catalent Inc
NYSE:CTLT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.18
61.29
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Catalent Inc
Catalent Inc
Cost of Revenue
Catalent Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Catalent Inc
NYSE:CTLT
|
Cost of Revenue
-$3.5B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-11%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cost of Revenue
-$27B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cost of Revenue
-$11.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cost of Revenue
-$17.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cost of Revenue
-$14.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cost of Revenue
-$7.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-4%
|
|
Catalent Inc
Glance View
Catalent Inc. is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for pharmaceuticals, biologics, and consumer health products. Founded in 2007, the company has rapidly grown its footprint by offering innovative solutions that enhance drug formulation and accelerate time to market. With a portfolio that spans from drug development to commercialization, Catalent’s core mission is to improve patient outcomes by ensuring that life-changing therapies reach those who need them. The company operates state-of-the-art manufacturing facilities across the globe, fostering strong partnerships with both small biotechnology firms and large pharmaceutical corporations to optimize their products and processes. As an investor, understanding Catalent's strategic direction is vital. The company capitalizes on the booming demand for biopharmaceuticals and personalized medicines, driven by trends in population aging and the ongoing need for advanced therapeutics. Catalent's commitment to research and innovation is evidenced by its robust R&D investments and a diverse range of proprietary technologies, such as its softgel and Zydis® orally disintegrating tablet technologies. Furthermore, the company's recent expansions and acquisitions signal a strategic focus on enhancing capacity and capabilities, positioning it well to thrive in a highly competitive market. By leveraging its extensive expertise and global scale, Catalent aims not only to enhance its service offerings but to deliver sustained value to its shareholders, making it a compelling option for those seeking exposure to the dynamic healthcare sector.
See Also
What is Catalent Inc's Cost of Revenue?
Cost of Revenue
-3.5B
USD
Based on the financial report for Sep 30, 2024, Catalent Inc's Cost of Revenue amounts to -3.5B USD.
What is Catalent Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-11%
Over the last year, the Cost of Revenue growth was -6%. The average annual Cost of Revenue growth rates for Catalent Inc have been -8% over the past three years , -14% over the past five years , and -11% over the past ten years .
You don't have any saved screeners yet
